Actinium pharmaceuticals inc pdf cactus ventures Wooderson

actinium pharmaceuticals inc pdf cactus ventures

Market Report Actinium Pharmaceuticals Inc. (ATNM Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, …

Exhibit 99.3 Pro forma Financial Information sec.gov

Actinium Pharmaceuticals Inc. ATNM (U.S quotes.wsj.com. Case: Reverse Merger between Actinium Pharmaceuticals Inc. and Cactus Ventures Inc. Public Company: Cactus Ventures Inc. Private Company: Actinium Pharmaceuticals Inc.As per a share exchange agreement dated December 28, 2012, Actinium Pharmaceuticals Inc., a New York based Biopharmaceutical Company went public via a reverse merger with Cactus Ventures, Inc., which …, ATNM / Actinium Pharmaceuticals, Inc. CURRENT REPORT (Current Report) 2018-02-26 sec.gov UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2018 ACTINIUM.

aac technologies holdings inc aadhaar ventures india ltd aadi industries ltd aag energy holdings ltd aagam capital ltd aak ab aalberts industries nv aalborg boldspilklub a/s aamaxan transport group inc aananda lakshmi spinning mills ltd aanchal ispat ltd aaon inc aap implantate ag aap inc aapico hitech pcl aar corp aarcon facilities ltd aareal bank ag aarey drugs & pharmaceuticals ltd aarhus Participating company list as of December 7, 2017 Company name Company type(s) Country 3D Signatures Medical device or technology Synthesis, analytic, diagnostic services Canada 3i Diagnostics, Inc. Synthesis, analytic, diagnostic services United States 3SBIO, INC Biotech or pharma, therapeutic R&D China 60 Degrees Pharmaceuticals Biotech or pharma, therapeutic R&D United States Aagami, Inc

Actinium Pharmaceuticals, Inc. is a publicly traded company. PrivCo specializes in private companies, but includes records on public companies like Actinium Pharmaceuticals, Inc. solely for their private market activity (such as investments into and acquisitions of private companies). securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

31/12/2018 · Dr. Rosemary Mazanet, M.D., Ph.D., is a Co-Founder of Apelles Investment Management, LP and serves as its Partner and Chief Scientific Officer. Dr. … He served as Director of Actinium Pharmaceuticals, Inc. from August 2012 to June 9, 2017. Dr. Traversa has more than 28 years of healthcare industry experience and is especially qualified to understand the risks and leadership challenges facing a growing pharmaceutical company from a senior management and financial expertise perspective. He served as a Director of Cactus Ventures, Inc. …

Exhibit 99.3. Unaudited pro forma combined financial information of Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. The unaudited pro forma information below gives effect to the share exchange between Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. as if it had been consummated as of the beginning of the applicable period. About Actinium Pharmaceuticals Actinium Pharmaceuticals, Inc. ( www.actiniumpharma.com ) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.

Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, … The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below.

Item 8.01 Other Events. Term Sheet with Actinium Pharmaceuticals, Inc. On August 30, 2012, Cactus Ventures, Inc. (the “Company”) entered into letter of intent (the “LOI”) with Actinium Pharmaceuticals, Actinium Pharmaceuticals, Inc. [ formerly Cactus Ventures, Inc. ] DEF 14A 4 Description of SIC Industry 2834 — Pharmaceutical Preparations § Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final

Free to access research and investor meetings in a post-MiFID2 world. Actinium Pharmaceuticals Inc (ATNM-US): Resurgent radiation on the turn Recommendation OUTPERFORM Enza Guagenti is Former Chief Financial Officer at Actinium Pharmaceuticals, Inc. View Enza Guagenti’s professional profile on Relationship Science, the database of decision makers.

aac technologies holdings inc aadhaar ventures india ltd aadi industries ltd aag energy holdings ltd aagam capital ltd aak ab aalberts industries nv aalborg boldspilklub a/s aamaxan transport group inc aananda lakshmi spinning mills ltd aanchal ispat ltd aaon inc aap implantate ag aap inc aapico hitech pcl aar corp aarcon facilities ltd aareal bank ag aarey drugs & pharmaceuticals ltd aarhus Founder of Medeor, Inc., Sergio Traversa is a businessperson who has been at the helm of 6 different companies and currently is CEO, CFO, Director & Principal Accounting Officer at Relmada Therapeutics, Inc.

The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below. He served as Director of Actinium Pharmaceuticals, Inc. from August 2012 to June 9, 2017. Dr. Traversa has more than 28 years of healthcare industry experience and is especially qualified to understand the risks and leadership challenges facing a growing pharmaceutical company from a senior management and financial expertise perspective. He served as a Director of Cactus Ventures, Inc. …

The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below. Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with

sc13g10109002_09152016.htm SEC.gov. 1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page., Founder of Medeor, Inc., Sergio Traversa is a businessperson who has been at the helm of 6 different companies and currently is CEO, CFO, Director & Principal Accounting Officer at Relmada Therapeutics, Inc..

Actinium Pharmaceuticals Inc. lawinsider.com

actinium pharmaceuticals inc pdf cactus ventures

Participating Company List bio.org. He served as Director of Actinium Pharmaceuticals, Inc. from August 2012 to June 9, 2017. Dr. Traversa has more than 28 years of healthcare industry experience and is especially qualified to understand the risks and leadership challenges facing a growing pharmaceutical company from a senior management and financial expertise perspective. He served as a Director of Cactus Ventures, Inc. …, The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below..

Actinium Pharmaceuticals Simply Wall St

actinium pharmaceuticals inc pdf cactus ventures

How These Biotech Stocks are Faring-- Actinium Pharma. Please join us as a sponsor of the 7th Annual Gateway Conference, being held September 5-6, 2018 at the Four Seasons in San Francisco, California. You will have a … Actinium Pharmaceuticals, Inc. (ATNM) Actinium is developing its CD33 program for hematologic indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) ….

actinium pharmaceuticals inc pdf cactus ventures


Enza Guagenti is Chief Financial Officer at Actinium Pharmaceuticals Inc/NJ. See Enza Guagenti's compensation, career history, education, & memberships. October 16, 2017 Actinium Pharmaceuticals to Present at BIO Investor Forum - Actinium to present on Tuesday, October 17th at 3 PM PT NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.

Founder of Medeor, Inc., Sergio Traversa is a businessperson who has been at the helm of 6 different companies and currently is CEO, CFO, Director & Principal Accounting Officer at Relmada Therapeutics, Inc. Actinium Pharmaceuticals had a pro forma cash position of $15.7m at 30 June 2014, after taking into account the proceeds from the $13.7m ($12.6m net) equity raise at $7.50 per share, which was completed in July.

Last Friday, shares in New York headquartered Actinium Pharmaceuticals Inc. ended the session 1.38% lower at $1.43. The stock recorded a trading volume of … The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below.

Explanatory Note: This Form 8-K/A includes the exhibits that Cactus Ventures, Inc. was unable to include, due to size limitations. to the Form 8-K submitted to the Securities and Exchange Commission (SEC) on January 2, 2013. Actinium Pharmaceuticals, Inc. [ formerly Cactus Ventures, Inc. ] DEF 14A 4 Description of SIC Industry 2834 — Pharmaceutical Preparations § Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final

Actinium Pharmaceuticals, Inc Biotech or pharma, therapeutic R&D United States Actinogen Medical Biotech or pharma, therapeutic R&D Australia Adagene Inc. Biotech or pharma, therapeutic R&D China Adan Medical Innovation Medical device or technology Spain Adare Pharmaceuticals Biotech or pharma, animal health Other products or services Other R&D services United States ADial Pharmaceuticals… Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is head

He served as Director of Actinium Pharmaceuticals, Inc. from August 2012 to June 9, 2017. Dr. Traversa has more than 28 years of healthcare industry experience and is especially qualified to understand the risks and leadership challenges facing a growing pharmaceutical company from a senior management and financial expertise perspective. He served as a Director of Cactus Ventures, Inc. … 10-Feb-17, subject to change Thursday, February 16, 2017 8:00 am REGISTRATION / BREAKFAST Track 1 – Tribeca Track 2 – Murray Hill 8:30 Cellectar Biosciences.

MERGENT ® INDUSTRIAL WEEKLY INDEX Published Every Tuesday Online and Printed Monthly Tuesday, June 05, 2018 Volume 89 No. 6 NOTICE – Items in … Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

Actinium Pharmaceuticals, Inc Biotech or pharma, therapeutic R&D United States Actinogen Medical Biotech or pharma, therapeutic R&D Australia Adagene Inc. Biotech or pharma, therapeutic R&D China Adan Medical Innovation Medical device or technology Spain Adare Pharmaceuticals Biotech or pharma, animal health Other products or services Other R&D services United States ADial Pharmaceuticals… Reverse Mergers: The Way Forward www.iosrjournals.org 26 Page trade under the name Cactus Ventures, Inc. until such time as the intended name change to Actinium Pharmaceuticals, Inc. takes effect [25] . The Company would continue to exchange its shares of common stock for shares of Actinium held by the remaining Actinium shareholders and would urge existing Actinium …

Dr. Dragan Cicic is Chief Technology Officer at Actinium Pharmaceuticals, Inc. Dr. Cicic was previously employed as Chief Operating & Medical Officer by Cactus Ventures, Inc., Director, Chief Operating & Medical Officer by Actinium Pharmaceuticals, Inc. /Old/, a Principal by British Broadcasting Corp., and Project Director by QED Technologies International, Inc. Actinium Pharmaceuticals is based out of New York. Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies.

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone Forward-Looking Statement for Actinium Pharmaceuticals, Inc. This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.

actinium pharmaceuticals inc pdf cactus ventures

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. He also served on the board at Cactus Ventures, Inc. and Actinium Pharmaceuticals, Inc. /Old/. He received his undergraduate degree from The University of Manchester and a doctorate degree from

Actinium Pharmaceuticals Inc. MarketWatch

actinium pharmaceuticals inc pdf cactus ventures

sc13g10109002_09152016.htm SEC.gov. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. Effective, Item 8.01 Other Events. Term Sheet with Actinium Pharmaceuticals, Inc. On August 30, 2012, Cactus Ventures, Inc. (the “Company”) entered into letter of intent (the “LOI”) with Actinium Pharmaceuticals,.

CACTUS VENTURES INC. SCHEDULE 14C INFORMATION

Join us as a Sponsor of the 7th Annual 2018 Gateway Conference. Free to access research and investor meetings in a post-MiFID2 world. Actinium Pharmaceuticals Inc (ATNM-US): Resurgent radiation on the turn Recommendation OUTPERFORM, aac technologies holdings inc aadhaar ventures india ltd aadi industries ltd aag energy holdings ltd aagam capital ltd aak ab aalberts industries nv aalborg boldspilklub a/s aamaxan transport group inc aananda lakshmi spinning mills ltd aanchal ispat ltd aaon inc aap implantate ag aap inc aapico hitech pcl aar corp aarcon facilities ltd aareal bank ag aarey drugs & pharmaceuticals ltd aarhus.

Actinium Pharmaceuticals, Inc Biotech or pharma, therapeutic R&D United States Actinogen Medical Biotech or pharma, therapeutic R&D Australia Adagene Inc. Biotech or pharma, therapeutic R&D China Actinium Pharmaceuticals had a pro forma cash position of $15.7m at 30 June 2014, after taking into account the proceeds from the $13.7m ($12.6m net) equity raise at $7.50 per share, which was completed in July.

31/12/2018 · Dr. Rosemary Mazanet, M.D., Ph.D., is a Co-Founder of Apelles Investment Management, LP and serves as its Partner and Chief Scientific Officer. Dr. … About: Actinium Pharmaceuticals, Inc. (ATNM) View as PDF UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN

On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. Effective Dr. Dragan Cicic is Chief Technology Officer at Actinium Pharmaceuticals, Inc. Dr. Cicic was previously employed as Chief Operating & Medical Officer by Cactus Ventures, Inc., Director, Chief Operating & Medical Officer by Actinium Pharmaceuticals, Inc. /Old/, a Principal by British Broadcasting Corp., and Project Director by QED Technologies International, Inc.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See В§ 240.13d-7 for other parties to whom copies are to be sent. Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is head

Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company that develops drugs for the treatment of cancer. Its pipeline products include Iomab-B whi Founder of Medeor, Inc., Sergio Traversa is a businessperson who has been at the helm of 6 different companies and currently is CEO, CFO, Director & Principal Accounting Officer at Relmada Therapeutics, Inc.

Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, … Founder of Medeor, Inc., Sergio Traversa is a businessperson who has been at the helm of 6 different companies and currently is CEO, CFO, Director & Principal Accounting Officer at Relmada Therapeutics, Inc.

ATNM / Actinium Pharmaceuticals, Inc. CURRENT REPORT (Current Report) 2018-02-26 sec.gov UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2018 ACTINIUM Last Friday, shares in New York headquartered Actinium Pharmaceuticals Inc. ended the session 1.38% lower at $1.43. The stock recorded a trading volume of …

078800630 Actinium Pharmaceuticals, Inc. USA ATNM AMEX 147372424 Adsouth Partners, Inc. USA ASPR Over The Counter 557410318 Advanced Life Sciences Holdings, Inc… Last Friday, shares in New York headquartered Actinium Pharmaceuticals Inc. ended the session 1.38% lower at $1.43. The stock recorded a trading volume of …

About: Actinium Pharmaceuticals, Inc. (ATNM) View as PDF UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN About Actinium Pharmaceuticals Actinium Pharmaceuticals, Inc. ( www.actiniumpharma.com ) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.

Dr. Dragan Cicic is Chief Technology Officer at Actinium Pharmaceuticals, Inc. Dr. Cicic was previously employed as Chief Operating & Medical Officer by Cactus Ventures, Inc., Director, Chief Operating & Medical Officer by Actinium Pharmaceuticals, Inc. /Old/, a Principal by British Broadcasting Corp., and Project Director by QED Technologies International, Inc. If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

t75355_sc13d.htm sec.gov

actinium pharmaceuticals inc pdf cactus ventures

Join us as a Sponsor of the 7th Annual 2018 Gateway Conference. Actinium Pharmaceuticals, Inc. (ATNM) Actinium is developing its CD33 program for hematologic indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) …, Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options..

AN OVERVIEW OF PIPER JAFFRAY’S 2017 HEARTLAND SUMMIT

actinium pharmaceuticals inc pdf cactus ventures

How These Biotech Stocks are Faring-- Actinium Pharma. The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below. Actinium Pharmaceuticals, Inc. [ formerly Cactus Ventures, Inc. ] DEF 14A 4 Description of SIC Industry 2834 — Pharmaceutical Preparations § Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final.

actinium pharmaceuticals inc pdf cactus ventures


Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See В§ 240.13d-7 for other parties to whom copies are to be sent. October 16, 2017 Actinium Pharmaceuticals to Present at BIO Investor Forum - Actinium to present on Tuesday, October 17th at 3 PM PT NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc. This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Actinium Pharmaceuticals had a pro forma cash position of $15.7m at 30 June 2014, after taking into account the proceeds from the $13.7m ($12.6m net) equity raise at $7.50 per share, which was completed in July.

078800630 Actinium Pharmaceuticals, Inc. USA ATNM AMEX 147372424 Adsouth Partners, Inc. USA ASPR Over The Counter 557410318 Advanced Life Sciences Holdings, Inc… Free to access research and investor meetings in a post-MiFID2 world. Actinium Pharmaceuticals Inc (ATNM-US): Resurgent radiation on the turn Recommendation OUTPERFORM

Actinium Pharmaceuticals, Inc Biotech or pharma, therapeutic R&D United States Actinogen Medical Biotech or pharma, therapeutic R&D Australia Adagene Inc. Biotech or pharma, therapeutic R&D China Actinium Pharmaceuticals Inc. $16.1 million Follow-on US 29-Jul-17 Kamada Ltd. $15 million Follow-on Israel 29-Jul-17 Tetraphase Pharmaceuticals Inc. $65 million Follow-on US 29-Jul-17

Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is head building revenue-generating relationships is rodman & ren shaw’s specialty. our world-renowned conferences and events provide us with platforms to make unforgettable in troductions.

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone 10-Feb-17, subject to change Thursday, February 16, 2017 8:00 am REGISTRATION / BREAKFAST Track 1 – Tribeca Track 2 – Murray Hill 8:30 Cellectar Biosciences.

Actinium Pharmaceuticals, Inc Biotech or pharma, therapeutic R&D United States Actinogen Medical Biotech or pharma, therapeutic R&D Australia Adagene Inc. Biotech or pharma, therapeutic R&D China The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below.

Actinium Pharmaceuticals, Inc. [ formerly Cactus Ventures, Inc. ] DEF 14A 4 Description of SIC Industry 2834 — Pharmaceutical Preparations § Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final ATNM / Actinium Pharmaceuticals, Inc. CURRENT REPORT (Current Report) 2018-02-26 sec.gov UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2018 ACTINIUM

The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below. Explanatory Note: This Form 8-K/A includes the exhibits that Cactus Ventures, Inc. was unable to include, due to size limitations. to the Form 8-K submitted to the Securities and Exchange Commission (SEC) on January 2, 2013.

Actinium Pharmaceuticals had a pro forma cash position of $15.7m at 30 June 2014, after taking into account the proceeds from the $13.7m ($12.6m net) equity raise at $7.50 per share, which was completed in July. The Amended 13D reflects, among other matters, the removal of AHLB and AHL as reporting persons and the entry by MSK into an Investors’ Rights Agreement with Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), on December 21, 2015, described in Item 6 below.

About Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. (OTCBB: ATNM) is a New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies. from Cactus Ventures, Inc. to Actinium Pharmaceutic als, Inc. became effective in accordance with Artic les of Merger filed with the State of Nevada and a Certificate of Merger filed with the S tate of Delaware. In connection with the name chan ge we also changed (i) the name of our subsidiary Actinium Pharmaceuticals, Inc. to Actini um Corporation, (ii) our par value to $0.001 per sh are, and